Plain-English translation of NCT07910708 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called for people with certain blood cancers (non-Hodgkin lymphoma or acute lymphoblastic leukemia) that have come back or stopped responding to other treatments. works by using a special virus to deliver genetic instructions into your body, teaching your own immune cells to recognize and attack cancer cells. The main goal right now is to find the safest dose and see how well the medication works.
Standard treatments don't work well enough for everyone with these aggressive blood cancers, and many patients relapse or become resistant to current therapies. Researchers believe this new genetic approach could offer hope to patients who have run out of other options by harnessing the body's own immune system in a completely new way.
You likely qualify if…
You likely don't qualify if…
You would receive the medication through an IV infusion into your bloodstream. The trial starts with smaller doses and gradually increases them as researchers confirm safety in earlier groups. You'll need regular visits for blood tests, scans, and medical exams to monitor how your body responds, check for side effects, and see if the cancer improves. Long-term follow-up visits will continue after your initial treatment to track your health over time.
AI-generated summary from trial data · Nov 17, 2026 · Not medical advice
China